NeuroEchos has officially registered and commenced operations of its East China Headquarters and R&D Center in Nanjing as of January 20, 2026, marking a major step in the commercialization of advanced brain-computer interface technologies.

The company plans to invest RMB 30 million to build a high-standard GMP manufacturing facility, supporting the registration and production of Class II and Class III invasive BCI medical devices. Annual sales are projected to exceed RMB 100 million.

Founded in 2017, NeuroEchos focuses on the clinical translation of invasive brain-computer interface technologies. In 2024, it obtained the world’s first Class III registration certificate for a 3.0T MRI-compatible SEEG intracranial deep electrode, positioning the company at the forefront of neurotechnology regulation and safety.

With its Nanjing base now operational, the company is accelerating the transition of brain science from laboratory research to real-world medical applications.